Dominant stargardt-like macular dystrophy
Distrofia macular Stargardt-like dominante
Distrofia Macular Stargardt- Like Dominante

Felipe Di Domenico - Pontifícia Universidade Católica do Rio Grande do Sul - PUC-RS, Porto Alegre, RS, Brasil. feliped@outlook.com
Felipe Kenzo Ishida - Faculdade Evangélica do Paraná, Curitiba, PR, Brasil. fe_kenzo@hotmail.com
Murilo Simão Cenovicz - Universidade Positivo, Curitiba, PR, Brasil. muca_sc@hotmail.com

ABSTRACT
Stargardt disease is a rare early-onset macular dystrophy, which progressively affects central visual acuity. In most cases, it is caused by an autosomal recessive inheritance. Here, we present the case of a family with Stargardt disease caused by autosomal dominant inheritance, together with a description of their history, clinical findings, and pertinent complementary examinations.

RESUMO
A doença de Stargardt é uma rara distrofia macular de início precoce que afeta progressivamente a acuidade visual central. Na maior parte das vezes é causada por uma herança autossômica recessiva. Apresentamos o caso de uma família com doença de Stargardt causada por herança autossômica dominante, descrevendo sua história, achados clínicos e exames complementares relevantes.

RESUMEN
La enfermedad de Stargardt es una rara distrofia macular de inicio precoz que afecta progresivamente la acuidad visual central. En la mayoría de veces, es causada por una herencia autósómica recesiva. Presentamos el caso de una familia con enfermedad de Stargardt causada por herencia autósómica dominante, describiendo su historia, hallazgos clínicos y análisis complementarios relevantes.

Keywords:
Macular Degeneration; Retinal Cone Photoreceptor Cells; Macular Dystrophy; ELOVL4 Protein, Human

Palavras-Chave: Degeneração Macular; Células Fotorreceptoras Retinianas Cones; Distrofia Macular; Proteína humana ELOVL4

Palabras Clave: Degeneración Macular; Células Fotorreceptoras Retinianas Conos; Distrofía Macular; ELOVL4 Proteína humana

Funding source: None
CEP Approval: Not applicable
Conflicts of interest: None
Received on: November 13, 2016
Approved on: November 29, 2016
Published on: March 24, 2017

INTRODUCTION

Stargardt disease (STGD) is the most common recessive macular dystrophy, and is characterized by decreased central vision, atrophy of the macula and the underlying retinal pigment epithelium, and frequent presence of yellowish flecks in the retinal posterior pole. Clinical manifestations of the disease vary depending on its genotype, as well as on the sensitivity of the foveal cones and the retinal pigmented epithelium (RPE). Low visual acuity is the most common clinical manifestation, and may vary from 20/30 to 20/200 whereas age of onset can vary from 5 to 50 years.

Clinical manifestations observed in the fundus include sparse yellowish flecks, which reflect the accumulation of bisretinoids underlying the RPE, and atrophy of the RPE in the macular region, which is often, described as resembling “beaten bronze.” Examination by fluorescein angiography (FA) shows that bisretinoids that have accumulated adjacent to the choroid can block light excitation of the dye in the choroidal circulation, which is known as “choroidal silence,” thus leaving the retinal vessels exposed in a deep hypofluorescence. Other signs include RPE atrophy, “bull’s eye” maculopathy, hyperfluorescent flecks, and preservation of peridiscal RPE (peripapillary sparing).

Genetically, STGD is a heterogeneous disorder, mostly inherited as an autosomal recessive disorder, and very rarely as an autosomal dominant trait with a late onset of clinical symptoms. A locus corresponding to a recessive allele was mapped on chromosome 1p (STGD Type 1). This gene encodes a retina-specific transmembrane protein, ABCA4, which belongs to the ATP Binding Cassette (ABC) membrane transporter group. Few cases of families diagnosed with Stargardt disease related to inheritance of an autosomal dominant trait were described, such as the mapping of a locus on chromosome 13q (STGD type 2), chromosome 6q (STGD Type 3), and chromosome 4p (STGD Type 4).

Dominant Stargardt-like macular dystrophy (Stargardt disease Type 3) was first described by Stone et al., in 1994, in large family that exhibited a phenotype that was similar to Stargardt disease that then led to the mapping of the gene on chromosome 6q. In 2011, Zhang et al. identified a deletion of 5 base pairs from the ELOVL4 (Elongation Of Very Long Chain Fatty Acids) gene on chromosome 6q in five families affected by this disease. Conversely, also in 2011, Bernstein et al. identified a complex heterozygous mutation in the ELOVL4 gene, wherein two deletions of a single base pair each, separated by 4 nucleotides, resulted in a frameshift in the gene and consequent truncation of the protein ELOVL4, indicating that the phenotype resulting from these mutations varies greatly among patients.

The ELOVL4 gene encodes an enzyme in the endoplasmic reticulum responsible for the biosynthesis of fatty acids that contain more than 26 carbon atoms. This enzyme is expressed in the brain and retina, where its expression is restricted to photoreceptor cells. Mutations associated with STGD Type 3 compromise the mutated enzyme’s trafficking, which results in an accumulation of lipofuscin, leading to death of photoreceptor cells.

The clinical manifestations of STGD Type 3 are very similar to those found in STGD Type 1. Deposits of lipofuscin in STGD Type 3 tend to be somewhat larger than the ones observed on STGD Type 1, and they often exhibit a “butterfly” appearance near macular injuries. The RPE is usually normal, and examination by fluorescein angiography shows a lower prevalence of silent choroid.

Here, we report the case of a family diagnosed with Stargardt disease Type 3, together with a description of their history, clinical findings, and pertinent complementary examinations.

CASE REPORT

PATIENT 1

Female, 47 years old. Main complaint: “blurry vision.”

Current medical history: The patient reported a progressive worsening of her visual acuity throughout her life, but it had become worse in the last 3 years. She had symptoms in both eyes, with greater intensity in the right eye. The patient reported that doctors from another clinic suspected retinal dystrophy approximately 10 years earlier, but no further investigation was done. The patient did not have a history of systemic diseases, surgeries, hospitalizations, nor allergies.

Family history: The patient reported that her mother, siblings, and daughter were suspected to have retinal dystrophy.
Physical Examination:

Ophthalmic examination showed a visual acuity of 20/400 in the right eye (RE) and 20/200 in the left eye (LE), both with the best optical correction. Results of biomicroscopy showed no changes, and the tonometry test measured pressure of 15 mmHg in both eyes (BE). Fundoscopic examination showed diffuse atrophy of the RPE with the presence of sparse hazy flecks in both eyes (Figure 1). Fluorescein angiography showed hyperfluorescence due to a window defect of the macular and perimacular area, exhibiting a coalescent aspect of hyperfluorescent dots up to the late phases (Figure 2). Optical coherence tomography revealed changes in the ellipsoid layer with loss of photoreceptors (Figure 3).

Figure 1. Retinography showing diffused atrophy of the RPE and dotted perimacular flecks.

Retinography with red-free light showing perimacular hyperautofluorescent flecks.
Figure 2. Fluorescein angiography showing hyperfluorescence due to a window defect of the macular and perimacular area.
FAMILY INVESTIGATION

PATIENT 2

The brother (male, age 39 years) of Patient 1 came to our hospital. He brought his electroretinogram results showing a photopic change. When questioned about his eye symptoms, the patient described intense photophobia. Eye examination showed a visual acuity of 20/30 in the RE and 20/80 in LE, with the best optical correction in BE. Results of biomicroscopy showed no changes, and the tonometry test measured 12 mmHg pressure in BE.

Fundoscopic evaluation revealed a diffuse atrophy of the RPE, in addition to a macula with beaten bronze appearance and the presence of punctiform flecks in the perimacular region in both eyes (Figure 4 A-B). On imaging with red-free light filter, bull’s eye maculopathy was observed, with perimacular and foveal hyperautofluorescent areas as well as punctiform atrophies in the central RPE (Figure 4 C-D). Fluorescein angiography showed hyperfluorescence due to a window defect of the macular and perimacular area, exhibiting a coalescent aspect of hyperfluorescent dots up to the late phases (Figure 5). Optical coherence tomography revealed foveal deposits and changes in the ellipsoid layer of photoreceptors (Figure 6).
Figure 4 A and B. Retinography showing a diffuse atrophy of the retinal pigmented epithelium, macula with beaten bronze appearance, and presence of punctiform flecks in the perimacular region in both eyes. C and D. Red-free light filter shows bull’s eye maculopathy with hyperautofluorescent perimacular and foveal areas as well as punctiform atrophy in the central RPE.
Figure 5. Fluorescein angiography showing both a hyperfluorescent central area due to a window defect of the macula and a diffuse atrophy of the RPE.
FAMILY INVESTIGATION

PATIENT 3

The daughter (female, age 29 years) of Patient 1 came to the hospital. She had no ocular symptoms, but reported a prior diagnosis of systemic lupus erythematosus and polyarteritis nodosa. In addition, she had suffered traumatic rupture of a knee ligament 3 weeks earlier. Optometry revealed a visual acuity of 20/20 in the RE and 20/25 in the LE, with the best optical correction in BE. Results of biomicroscopy showed no changes, and tonometry test measured 12 mmHg pressure in BE. Fundoscopic evaluation revealed a beaten bronze appearance in the macular region, atrophy of the RPE in the central retinal region, and the presence of sparse flecks in the perimacular region in BE (Figure 7).

Fluorescein angiography showed an intense choroidal silence, with contrast between the retinal vessels and the dark background of the choroid. There were dotted hyperfluorescent areas caused by a window defect in the macular and perimacular area in BE (Figure 8). Optical coherence tomography revealed deposits underneath the RPE and changes in the ellipsoid layer (Figure 9).
Figure 7. Retinography showing a beaten bronze appearance in the macular region in BE, RPE atrophy located in the central region and hyperautofluorescent dotted areas in the perimacular region.
Figure 8. Fluorescein angiography showing an intense choroidal silence, with a clear visualization of retinal vessels in contrast with the dark background of the choroid. There is a dotted hyperfluorescent area caused by a window defect in the macular and perimacular area in BE.
DISCUSSION

The recessive form of Stargardt disease is the most common hereditary macular dystrophy, representing 7% of retinal dystrophies. In contrast, Stargardt-like macular dystrophy (STGD Type 3) has been reported only in a few cases in the literature, being an atypical disease even in specialized medical centers. According to Fishman, the initial diagnosis of recessive Stargardt disease is more prevalent in the age range 20–29. Studies did not report any data pertaining to age of the initial diagnosis in patients with autosomal dominant Stargardt disease. Our 3 patients, aged 47, 39, and 29 years, were only diagnosed in our clinic.

STGD patients frequently experience photophobia, and they seem to have better night vision, which was reported by Patient 2. Our patients presented with normal color vision, which was to be expected according to reports in the literature. Usually, altered color vision is not observed in patients with dominant Stargardt disease.

Edwards et al. found visual acuity in Stargardt Type 3 patients ranging from 20/20 to 20/800, and most patients older than 30 years presented with vision 20/200 or worse. After reaching a visual acuity of 20/200, progression is slow, which is different from that in recessive Stargardt disease. Surprisingly, our findings showed the opposite: Patient 2, 39 years old, presented with a visual acuity of 20/30 in the RE and 20/80 in the LE, and Patient 3, 29 years old, presented with a visual acuity of 20/20 in the RE and 20/25 in the LE, whereas Patient 1, 47 years old, presented with a visual acuity of 20/200 in the RE and 20/400 in LE, as reported in the literature.

Edwards et al. studied two families with Stargardt disease Type 3, and found patterns for changes observed in the fundoscopic examination according to disease stage. Initial findings included sub-foveal atrophy of the RPE, associated with an area of window defect of the macula on fluorescein angiography. Over the years, there would be an increased atrophy of the RPE that resembles the stained lesions observed in patients with recessive Stargardt disease. Flecks were generally absent at that stage. Over several years, in most patients, injuries have evolved to a well-circumscribed retinal area, RPE atrophy, and a choroid of increasing size that is associated with flecks. The atrophic lesion often had a beaten bronze appearance. We did not have the opportunity to conduct a horizontal follow-up of patients at the time of the study. However, fundoscopic changes found in our three patients match the findings described by Edwards et al.

Families with autosomal dominant Stargardt macular dystrophy linked to chromosomes 6q14 and 13q34 display a similar fundus phenotype. According to Edwards et al., families linked to 6q14 do not have the dark choroid observed in recessive Stargardt disease.
and it is not known whether the families linked to 13q34 exhibit choroidal silence. Lopez et al. described a family with an autosomal dominant Stargardt macular dystrophy that presented choroidal silence\(^2\). In our patients, fluorescein angiography detected choroidal silence in Patient 3 (Figure 8). Ryan et al. reported that deposits of lipofuscin in STGD Type 3 tend to be somewhat larger than in STGD Type 1, and often have the appearance of a butterfly near the macular injuries\(^2\). The lipofuscin deposits were small in our three patients, and they did not have a butterfly appearance.

**REFERENCES**


Felipe Di Domenico
http://orcid.org/0000-0002-3545-7604
http://lattes.cnpq.br/9091160125153793